Jazz Pharmaceuticals (JAZZ) Cash & Equivalents (2010 - 2026)

Jazz Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 0.95% year-over-year to $1.8 billion in Q1 2026; TTM through Mar 2026 was $1.8 billion, a 0.95% decrease from a year earlier, with the FY2025 full-year figure at $1.4 billion, down 42.31% from the prior year.
• Cash & Equivalents grew to $1.8 billion in Q1 2026 per JAZZ's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $2.4 billion in Q4 2024 and bottomed at $490.8 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $1.3 billion (2023), against an average of $1.4 billion.
• Across the five-year window, Cash & Equivalents slumped 76.6% in 2022 and jumped 137.94% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $881.5 million in 2022, then surged by 70.88% to $1.5 billion in 2023, then jumped by 60.18% to $2.4 billion in 2024, then tumbled by 42.31% to $1.4 billion in 2025, then surged by 32.5% to $1.8 billion in 2026.
• Per Business Quant, the three latest JAZZ Cash & Equivalents figures stand at $1.8 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.3 billion (Q3 2025).